Published in Proc Natl Acad Sci U S A on November 16, 2010
Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol (2012) 12.19
History of myeloid-derived suppressor cells. Nat Rev Cancer (2013) 3.14
Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell (2011) 2.96
Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A (2012) 2.23
Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. Sci Transl Med (2016) 2.06
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature (2015) 2.04
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest (2011) 1.90
G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation. Cancer Res (2015) 1.74
S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell (2012) 1.64
Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One (2011) 1.55
Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nat Cell Biol (2016) 1.49
CD8+ T-cell immunosurveillance constrains lymphoid premetastatic myeloid cell accumulation. Eur J Immunol (2014) 1.43
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun (2016) 1.39
The anti-tumor effect of the quinoline-3-carboxamide tasquinimod: blockade of recruitment of CD11b(+) Ly6C(hi) cells to tumor tissue reduces tumor growth. BMC Cancer (2016) 1.39
Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med (2014) 1.29
Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Adv Cancer Res (2015) 1.25
Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc Natl Acad Sci U S A (2013) 1.25
The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment. Cancer Microenviron (2014) 1.24
Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci U S A (2014) 1.24
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Trends Immunol (2016) 1.20
Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc Natl Acad Sci U S A (2015) 1.17
Protumor and antitumor functions of neutrophil granulocytes. Semin Immunopathol (2012) 1.17
microRNA-mediated regulation of the tumor microenvironment. Cell Cycle (2013) 1.14
Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. Cancer Res (2014) 1.08
Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest (2015) 1.07
Neutrophils in cancer: neutral no more. Nat Rev Cancer (2016) 1.06
Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity (2014) 1.01
Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression. Oncogene (2012) 1.00
Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b+Gr1+ cells: key role of Stat3 signaling. J Biol Chem (2012) 0.98
Increased circulation of galectin-3 in cancer induces secretion of metastasis-promoting cytokines from blood vascular endothelium. Clin Cancer Res (2013) 0.97
Intravital imaging reveals distinct responses of depleting dynamic tumor-associated macrophage and dendritic cell subpopulations. Proc Natl Acad Sci U S A (2014) 0.95
Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. Front Oncol (2014) 0.94
G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist. Blood (2011) 0.94
The new deal: a potential role for secreted vesicles in innate immunity and tumor progression. Front Immunol (2015) 0.93
Neutrophil extracellular traps: A new link to cancer-associated thrombosis and potential implications for tumor progression. Oncoimmunology (2013) 0.93
The impact of the myeloid response to radiation therapy. Clin Dev Immunol (2013) 0.92
Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA. Br J Cancer (2012) 0.92
Radiation promotes invasiveness of non-small-cell lung cancer cells through granulocyte-colony-stimulating factor. Oncogene (2015) 0.91
Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1. Cancer Res (2012) 0.91
Neutrophils in Cancer: Two Sides of the Same Coin. J Immunol Res (2015) 0.90
Neutrophils Suppress Intraluminal NK Cell-Mediated Tumor Cell Clearance and Enhance Extravasation of Disseminated Carcinoma Cells. Cancer Discov (2016) 0.89
Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer. Cancer J (2013) 0.88
Transcriptional regulation of myeloid-derived suppressor cells. J Leukoc Biol (2015) 0.88
Myeloid clusters are associated with a pro-metastatic environment and poor prognosis in smoking-related early stage non-small cell lung cancer. PLoS One (2013) 0.86
Tissue inhibitor of metalloproteinases (TIMP)-1 creates a premetastatic niche in the liver through SDF-1/CXCR4-dependent neutrophil recruitment in mice. Hepatology (2014) 0.86
A role for G-CSF and GM-CSF in nonmyeloid cancers. Cancer Med (2014) 0.85
Does the mobilization of circulating tumour cells during cancer therapy cause metastasis? Nat Rev Clin Oncol (2016) 0.84
SHIP represses lung inflammation and inhibits mammary tumor metastasis in BALB/c mice. Oncotarget (2015) 0.84
Protumor activities of the immune response: insights in the mechanisms of immunological shift, oncotraining, and oncopromotion. J Oncol (2013) 0.84
CCL9 Induced by TGFβ Signaling in Myeloid Cells Enhances Tumor Cell Survival in the Premetastatic Organ. Cancer Res (2015) 0.84
The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumor. PLoS One (2013) 0.83
Circulating galectins -2, -4 and -8 in cancer patients make important contributions to the increased circulation of several cytokines and chemokines that promote angiogenesis and metastasis. Br J Cancer (2014) 0.83
TNFα-activated mesenchymal stromal cells promote breast cancer metastasis by recruiting CXCR2(+) neutrophils. Oncogene (2016) 0.82
Obesity alters the lung myeloid cell landscape to enhance breast cancer metastasis through IL5 and GM-CSF. Nat Cell Biol (2017) 0.82
Tumour cells coerce host tissue to cancer spread. Bonekey Rep (2013) 0.82
Systemic expression of Kaposi sarcoma herpesvirus (KSHV) Vflip in endothelial cells leads to a profound proinflammatory phenotype and myeloid lineage remodeling in vivo. PLoS Pathog (2015) 0.81
Distinct Functions of Neutrophil in Cancer and Its Regulation. Mediators Inflamm (2015) 0.80
Local and systemic neutrophilic inflammation in patients with lung cancer and chronic obstructive pulmonary disease. BMC Immunol (2013) 0.80
Preoperative NLR for predicting survival rate after radical resection combined with adjuvant immunotherapy with CIK and postoperative chemotherapy in gastric cancer. J Cancer Res Clin Oncol (2017) 0.79
S100A4-neutralizing antibody suppresses spontaneous tumor progression, pre-metastatic niche formation and alters T-cell polarization balance. BMC Cancer (2015) 0.79
A STING-dependent innate-sensing pathway mediates resistance to corneal HSV-1 infection via upregulation of the antiviral effector tetherin. Mucosal Immunol (2015) 0.79
Intraosseous inoculation of tumor cells into bone marrow promotes distant metastatic tumor development: A novel tool for mechanistic and therapeutic studies. Cancer Lett (2012) 0.79
Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. Front Immunol (2015) 0.78
Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response. PLoS One (2016) 0.78
Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal. Immunol Rev (2016) 0.78
Parallel Aspects of the Microenvironment in Cancer and Autoimmune Disease. Mediators Inflamm (2016) 0.78
On the origin of myeloid-derived suppressor cells. Oncotarget (2016) 0.78
G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer. Oncoimmunology (2015) 0.78
Expression of membrane anchored cytokines and B7-1 alters tumor microenvironment and induces protective antitumor immunity in a murine breast cancer model. Vaccine (2013) 0.78
Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types. Exp Mol Med (2016) 0.77
Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome. Oncoimmunology (2015) 0.77
Recruitment of myeloid cells to the tumor microenvironment supports liver metastasis. Oncoimmunology (2013) 0.77
The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer. Sci Rep (2015) 0.77
Genome-wide RNAi screening identifies genes inhibiting the migration of glioblastoma cells. PLoS One (2013) 0.77
Battle over CCL2 for control of the metastatic niche: neutrophils versus monocytes. Breast Cancer Res (2012) 0.77
Neutrophils: Critical components in experimental animal models of cancer. Semin Immunol (2016) 0.77
Neutrophils drive accelerated tumor progression in the collagen-dense mammary tumor microenvironment. Breast Cancer Res (2016) 0.76
Plasticity of neutrophils reveals modulatory capacity. Braz J Med Biol Res (2015) 0.76
ROR1C Regulates Differentiation of Myeloid-Derived Suppressor Cells. Cancer Cell (2015) 0.76
Arresting supporters: targeting neutrophils in metastasis. Cell Res (2016) 0.75
Paraneoplastic Leukemoid Reaction as a Marker of Tumor Progression in Non-Small Cell Lung Cancer. Cancer Treat Commun (2015) 0.75
Systemic inflammation: Cancer's long-distance reach to maximize metastasis. Oncoimmunology (2015) 0.75
The Essential Role of Type I Interferons in Differentiation and Activation of Tumor-Associated Neutrophils. Front Immunol (2016) 0.75
Intracellular IL-37b interacts with Smad3 to suppress multiple signaling pathways and the metastatic phenotype of tumor cells. Oncogene (2017) 0.75
G-CSF Is a Cancer Stem Cell-Specific Growth Factor-Response. Cancer Res (2015) 0.75
Arginine Metabolism in Myeloid Cells Shapes Innate and Adaptive Immunity. Front Immunol (2017) 0.75
Tumor-associated neutrophils display a distinct N1 profile following TGFβ modulation: A transcriptomics analysis of pro- vs. antitumor TANs. Oncoimmunology (2016) 0.75
IL-1β, IL-8, and Matrix Metalloproteinases-1, -2, and -10 Are Enriched upon Monocyte-Breast Cancer Cell Cocultivation in a Matrigel-Based Three-Dimensional System. Front Immunol (2017) 0.75
Platelet distribution width correlates with prognosis of gastric cancer. Oncotarget (2017) 0.75
NEUTROPHIL/LYMPHOCYTE RATIO AND PLATELET/LYMPHOCYTE RATIO IN PATIENTS WITH NSCLC. Mater Sociomed (2016) 0.75
Inhibiting MDSC differentiation from bone marrow with phytochemical polyacetylenes drastically impairs tumor metastasis. Sci Rep (2016) 0.75
Immune Regulation of the Metastatic Process: Implications for Therapy. Adv Cancer Res (2016) 0.75
One microenvironment does not fit all: heterogeneity beyond cancer cells. Cancer Metastasis Rev (2016) 0.75
Intravital FRET imaging reveals osteopontin-mediated polymorphonuclear leukocyte activation by tumor cell emboli. Cancer Sci (2016) 0.75
Label-Free Raman Spectroscopy Detects Stromal Adaptations in Premetastatic Lungs Primed by Breast Cancer. Cancer Res (2016) 0.75
Engineering the pre-metastatic niche. Nat Biomed Eng (2017) 0.75
Cancer antigen 15-3, platelet distribution width, and fibrinogen in combination to distinguish breast cancer from benign breast disease in non-conclusive mammography patients. Oncotarget (2017) 0.75
Energy metabolic pathways control the fate and function of myeloid immune cells. J Leukoc Biol (2017) 0.75
Cancer-associated pathways and biomarkers of venous thrombosis. Blood (2017) 0.75
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 15.57
Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17
Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol (1992) 12.96
Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res (1992) 9.02
Genes that mediate breast cancer metastasis to the brain. Nature (2009) 8.23
Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J Leukoc Biol (2007) 7.80
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol (2001) 7.43
The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer (2008) 7.40
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 6.78
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature (2009) 6.67
Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell (2009) 6.66
Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med (1991) 6.33
Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol (2006) 5.82
The metastatic niche: adapting the foreign soil. Nat Rev Cancer (2009) 5.28
MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell (2002) 4.93
Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus. Nature (2002) 4.67
The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells. Nature (1989) 4.43
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev (2008) 4.36
Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature (2007) 3.70
Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer (2008) 3.03
Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res (1978) 2.86
G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A (2009) 2.68
Blockade of S100A8 and S100A9 suppresses neutrophil migration in response to lipopolysaccharide. J Immunol (2003) 2.31
Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis (2006) 1.97
Regulation of neutrophil homeostasis. Curr Opin Hematol (2007) 1.87
Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol (2007) 1.84
Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res (2010) 1.83
Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int J Immunopharmacol (1999) 1.82
The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells. Proc Natl Acad Sci U S A (2003) 1.78
Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. Proc Natl Acad Sci U S A (2004) 1.75
Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study. Cancer (2009) 1.69
Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol (2008) 1.51
Matrix metalloproteinase-9 from bone marrow-derived cells contributes to survival but not growth of tumor cells in the lung microenvironment. Cancer Res (2006) 1.50
VEGFR1-activity-independent metastasis formation. Nature (2009) 1.47
Role of S100A8 and S100A9 in neutrophil recruitment in response to monosodium urate monohydrate crystals in the air-pouch model of acute gouty arthritis. Arthritis Rheum (2003) 1.32
The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory granulocytes and modulates inflammatory pain. Proc Natl Acad Sci U S A (2009) 1.24
Characterization and regulation of bv8 in human blood cells. Clin Cancer Res (2009) 1.21
Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res (2009) 1.20
Bladder tumor producing granulocyte colony-stimulating factor and parathyroid hormone related protein. J Urol (2002) 1.08
Lung large cell carcinoma producing granulocyte-colony-stimulating factor. Ann Thorac Surg (2007) 1.04
Granulocyte-colony-stimulating-factor-producing hepatocellular carcinoma. J Gastroenterol (1999) 0.97
Rapid clinical deterioration and leukemoid reaction after treatment of urothelial carcinoma of the bladder: possible effect of granulocyte colony-stimulating factor. J Clin Oncol (2009) 0.91
The first 2 cases of granulocyte colony-stimulating factor producing adenocarcinoma of the uterine cervix. Int J Gynecol Pathol (2010) 0.86
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66
Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell (2005) 21.01
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med (2008) 12.68
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83
The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 10.04
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 9.87
HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell (2003) 9.12
Annotation of the Drosophila melanogaster euchromatic genome: a systematic review. Genome Biol (2002) 8.59
Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ Res (2007) 8.44
A paracrine requirement for hedgehog signalling in cancer. Nature (2008) 8.16
Autocrine VEGF signaling is required for vascular homeostasis. Cell (2007) 7.37
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol (2007) 6.76
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest (2003) 6.44
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol (2008) 5.54
Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet (2003) 5.43
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature (2011) 5.32
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem (2002) 5.10
Recurrent R-spondin fusions in colon cancer. Nature (2012) 5.10
Heterochromatic sequences in a Drosophila whole-genome shotgun assembly. Genome Biol (2002) 5.09
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res (2005) 4.94
Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science (2003) 4.56
Therapeutic antibody targeting of individual Notch receptors. Nature (2010) 4.56
Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell (2009) 4.47
Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A (2002) 4.46
The External RNA Controls Consortium: a progress report. Nat Methods (2005) 4.24
VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature (2002) 4.10
Molecular imaging in drug development. Nat Rev Drug Discov (2008) 4.06
The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell (2003) 3.89
Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res (2009) 3.72
PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell (2009) 3.71
Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature (2007) 3.70
A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell (2010) 3.34
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem (2005) 3.30
Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell (2004) 3.28
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell (2002) 3.27
Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc Natl Acad Sci U S A (2002) 3.26
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol (2011) 3.23
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A (2012) 3.21
Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature (2011) 3.15
The vascular basement membrane: a niche for insulin gene expression and Beta cell proliferation. Dev Cell (2006) 3.10
The molecular basis of vascular lumen formation in the developing mouse aorta. Dev Cell (2009) 3.08
The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol (2007) 3.06
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol (2005) 3.00
Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res (2005) 3.00
An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med (2013) 3.00
Deconvolution of blood microarray data identifies cellular activation patterns in systemic lupus erythematosus. PLoS One (2009) 2.98
Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer (2010) 2.93
Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol (2011) 2.83
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res (2004) 2.81
Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res (2006) 2.75
Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res (2011) 2.71
Loss of the tumor suppressor BAP1 causes myeloid transformation. Science (2012) 2.69
G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A (2009) 2.68
Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res (2009) 2.65
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 2.64
Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell (2010) 2.64
Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. J Clin Invest (2012) 2.58
Role of VEGF-A in vascularization of pancreatic islets. Curr Biol (2003) 2.56
VEGFA is necessary for chondrocyte survival during bone development. Development (2004) 2.54
Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res (2010) 2.45
CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair. Blood (2012) 2.43
Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol (2005) 2.38
Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell (2008) 2.35
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res (2008) 2.33
Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol (2006) 2.32
Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci U S A (2008) 2.30
Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. Dev Biol (2003) 2.24